Q4 2017 13F Holders as of 31 Dec 2017
-
Type / Class
-
Equity / PHARMACEUTCL ETF
-
Number of holders
-
49
-
Total 13F shares, excl. options
-
1,567,774
-
Shares change
-
-1,132,141
-
Total reported value, excl. options
-
$93,015,784
-
Value change
-
-$67,109,351
-
Number of buys
-
18
-
Number of sells
-
-20
-
Price
-
$59.31
Significant Holders of VANECK ETF TRUST - PHARMACEUTCL ETF (PPH) as of Q4 2017
56 filings reported holding PPH - VANECK ETF TRUST - PHARMACEUTCL ETF as of Q4 2017.
VANECK ETF TRUST - PHARMACEUTCL ETF (PPH) has 49 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1,567,774 shares
.
Largest 10 shareholders include MEITAV DASH INVESTMENTS LTD (340,894 shares), GOLDMAN SACHS GROUP INC (250,135 shares), CITIGROUP INC (217,835 shares), CLS Investments, LLC (144,000 shares), UBS Group AG (97,026 shares), MORGAN STANLEY (91,720 shares), RAYMOND JAMES & ASSOCIATES (91,602 shares), BANK OF AMERICA CORP /DE/ (91,525 shares), Tower Research Capital LLC (TRC) (30,486 shares), and JANE STREET GROUP, LLC (27,756 shares).
This table shows the top 49 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.